Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 for Lymphopenic COVID-19 Patients
NCT04379076Phase 2Terminated
- Sponsor
- RevImmune
- Start
- May 2020
- Primary completion
- Feb 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant human interleukin-7 in coronavirus disease 2019 (COVID-19) and lymphocytopenia (2 arms), sponsored by RevImmune. Primary endpoint: Improvement of the absolute lymphocyte count at 30 days. Started May 2020; status: terminated.
02
Drugs
recombinant human interleukin-7
03
Conditions
coronavirus disease 2019 (COVID-19)lymphocytopenia
Beyond the preview
Go deeper on NCT04379076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04379076.